» Articles » PMID: 28949904

A Lethal Model of Disseminated Dengue Virus Type 1 Infection in AG129 Mice

Overview
Journal J Gen Virol
Specialty Microbiology
Date 2017 Sep 27
PMID 28949904
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The mosquito-borne disease dengue is caused by four serologically and genetically related flaviviruses termed DENV-1 to DENV-4. Dengue is a global public health concern, with both the geographical range and burden of disease increasing rapidly. Clinically, dengue ranges from a relatively mild self-limiting illness to a severe life-threatening and sometimes fatal disease. Infection with one DENV serotype produces life-long homotypic immunity, but incomplete and short-term heterotypic protection. The development of small-animal models that recapitulate the characteristics of the disseminated disease seen clinically has been difficult, slowing the development of vaccines and therapeutics. The AG129 mouse (deficient in interferon alpha/beta and gamma receptor signalling) has proven to be valuable for this purpose, with the development of models of disseminated DENV-2,-3 and -4 disease. Recently, a DENV-1 AG129 model was described, but it requires antibody-dependent enhancement (ADE) to produce lethality. Here we describe a new AG129 model utilizing a non-mouse-adapted DENV-1 strain, West Pacific 74, that does not require ADE to induce lethal disease. Following high-titre intraperitoneal challenge, animals experience a virus infection with dissemination to multiple visceral tissues, including the liver, spleen and intestine. The animals also become thrombocytopenic, but vascular leakage is less prominent than in AG129 models with other DENV serotypes. Taken together, our studies demonstrate that this model is an important addition to dengue research, particularly for understanding the pathological basis of the disease between DENV serotypes and allowing the full spectrum of activity to test comparisons for putative vaccines and antivirals.

Citing Articles

Progress and challenges in development of animal models for dengue virus infection.

Yuya W, Yuansong Y, Susu L, Chen L, Yong W, Yining W Emerg Microbes Infect. 2024; 13(1):2404159.

PMID: 39312399 PMC: 11423536. DOI: 10.1080/22221751.2024.2404159.


Electropenetrography with Alternating Current Reveals In Situ Changes of Probing Behaviors Associated with Dengue Virus Infection.

Jameson S, Vaughan L, de Verges J, Carter B, Dobek G, Londono-Renteria B Comp Med. 2024; 74(4):284-294.

PMID: 39074957 PMC: 11373679. DOI: 10.30802/AALAS-CM-24-030.


mRNA-encoded Cas13 can be used to treat dengue infections in mice.

Basu M, Zurla C, Auroni T, Vanover D, Chaves L, Sadhwani H Nat Microbiol. 2024; 9(8):2160-2172.

PMID: 38839984 DOI: 10.1038/s41564-024-01726-6.


The Dynamic Relationship between Dengue Virus and the Human Cutaneous Innate Immune Response.

Marti M, Castanha P, Barratt-Boyes S Viruses. 2024; 16(5).

PMID: 38793609 PMC: 11125669. DOI: 10.3390/v16050727.


Establishment of a lethal mouse model of emerging tick-borne orthonairovirus infections.

Ariizumi T, Tabata K, Itakura Y, Kobayashi H, Hall W, Sasaki M PLoS Pathog. 2024; 20(3):e1012101.

PMID: 38502642 PMC: 10980201. DOI: 10.1371/journal.ppat.1012101.


References
1.
Lee Y, Leong W, Wilder-Smith A . Markers of dengue severity: a systematic review of cytokines and chemokines. J Gen Virol. 2016; 97(12):3103-3119. DOI: 10.1099/jgv.0.000637. View

2.
Orozco S, Schmid M, Parameswaran P, Lachica R, Henn M, Beatty R . Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. J Gen Virol. 2012; 93(Pt 10):2152-2157. PMC: 3541791. DOI: 10.1099/vir.0.045088-0. View

3.
Rathakrishnan A, Wang S, Hu Y, Khan A, Ponnampalavanar S, Lum L . Cytokine expression profile of dengue patients at different phases of illness. PLoS One. 2013; 7(12):e52215. PMC: 3527385. DOI: 10.1371/journal.pone.0052215. View

4.
. Dengue vaccine: WHO position paper – July 2016. Wkly Epidemiol Rec. 2016; 91(30):349-64. View

5.
Hadinegoro S, Arredondo-Garcia J, Capeding M, Deseda C, Chotpitayasunondh T, Dietze R . Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med. 2015; 373(13):1195-206. DOI: 10.1056/NEJMoa1506223. View